JP2011529923A - 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法 - Google Patents

精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法 Download PDF

Info

Publication number
JP2011529923A
JP2011529923A JP2011521411A JP2011521411A JP2011529923A JP 2011529923 A JP2011529923 A JP 2011529923A JP 2011521411 A JP2011521411 A JP 2011521411A JP 2011521411 A JP2011521411 A JP 2011521411A JP 2011529923 A JP2011529923 A JP 2011529923A
Authority
JP
Japan
Prior art keywords
disorders
disorder
antiepileptic
dose
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011521411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529923A5 (cg-RX-API-DMAC7.html
Inventor
フィリップ・バード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gosforth Centre Holdings Pty Ltd
Original Assignee
Gosforth Centre Holdings Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008904016A external-priority patent/AU2008904016A0/en
Application filed by Gosforth Centre Holdings Pty Ltd filed Critical Gosforth Centre Holdings Pty Ltd
Publication of JP2011529923A publication Critical patent/JP2011529923A/ja
Publication of JP2011529923A5 publication Critical patent/JP2011529923A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011521411A 2008-08-06 2009-08-06 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法 Pending JP2011529923A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2008904016A AU2008904016A0 (en) 2008-08-06 Treatment for individuals with low dose anti-epileptic drugs or litium-based salts
AU2008904021A AU2008904021A0 (en) 2008-08-06 Therapeutic combinations for psychological disorders
AU2008904021 2008-08-06
AU2008904016 2008-08-06
PCT/AU2009/001000 WO2010015029A1 (en) 2008-08-06 2009-08-06 Compositions and methods for treating psychiatric disorders

Publications (2)

Publication Number Publication Date
JP2011529923A true JP2011529923A (ja) 2011-12-15
JP2011529923A5 JP2011529923A5 (cg-RX-API-DMAC7.html) 2014-04-10

Family

ID=41663218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521411A Pending JP2011529923A (ja) 2008-08-06 2009-08-06 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法

Country Status (8)

Country Link
US (2) US20110207718A1 (cg-RX-API-DMAC7.html)
EP (1) EP2331088A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011529923A (cg-RX-API-DMAC7.html)
CN (1) CN102170874A (cg-RX-API-DMAC7.html)
AU (1) AU2009279372A1 (cg-RX-API-DMAC7.html)
CA (1) CA2732131A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001384A (cg-RX-API-DMAC7.html)
WO (1) WO2010015029A1 (cg-RX-API-DMAC7.html)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510901A (ja) * 2012-03-23 2015-04-13 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ シネフリン及びトピラマートを含む組み合わせ製品
US9421188B2 (en) 2012-03-23 2016-08-23 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Combination product comprising phentermine and topiramate, and preparation method thereof
JP2016537435A (ja) * 2013-11-20 2016-12-01 ビオコデ 強迫神経症の薬理学的治療
JP2016540815A (ja) * 2013-12-18 2016-12-28 ビオコデ 注意欠陥及び／又は多動の治療における使用のためのベンゾジオキソール誘導体
JP2017528478A (ja) * 2014-09-10 2017-09-28 ロイヤル・ホロウェイ・アンド・ベッドフォード・ニュー・カレッジＲｏｙａｌ Ｈｏｌｌｏｗａｙ Ａｎｄ Ｂｅｄｆｏｒｄ Ｎｅｗ Ｃｏｌｌｅｇｅ 抗痙攣化合物
JP2018521127A (ja) * 2015-07-08 2018-08-02 ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
JP2018536688A (ja) * 2015-12-11 2018-12-13 オルフス ユニバーシテト 筋強直症の治療における使用のためのルフィナミド
JP2019520311A (ja) * 2016-05-12 2019-07-18 リサーチ トライアングル インスティテュート 神経伝達物質放出剤としてのビニローグフェネチルアミン
JP2021007038A (ja) * 2014-09-29 2021-01-21 ゾゲニクス インターナショナル リミテッド 薬物供給管理用の管理システム
US11406606B2 (en) 2016-08-24 2022-08-09 Zogenix International Limited Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
US11458111B2 (en) 2017-09-26 2022-10-04 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20230033195A1 (en) * 2011-02-09 2023-02-02 The Johns Hopkins University Methods and compositions for improving cognitive function
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11634377B2 (en) 2015-12-22 2023-04-25 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
US11673852B2 (en) 2015-12-22 2023-06-13 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
JP2024505283A (ja) * 2021-02-03 2024-02-05 マリオ サンチェス，エクトル 遂行機能障害の処置のための併用療法
US12097206B2 (en) 2013-05-03 2024-09-24 Katholieke Universiteit Leuven Method for the treatment of Dravet Syndrome
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
JP2011529923A (ja) 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
EP3260118B1 (en) 2008-10-16 2021-03-24 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2398760A1 (en) * 2009-02-20 2011-12-28 Aarhus Universitet Allosteric binding compounds
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
WO2011143721A1 (en) * 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US8883815B2 (en) 2011-05-19 2014-11-11 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy impaired speech in children
US10085414B2 (en) 2011-05-19 2018-10-02 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
US20140163070A1 (en) * 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
US9682073B2 (en) 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
US9040082B2 (en) * 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
GB201111712D0 (en) * 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
SG11201404212YA (en) * 2012-01-18 2014-10-30 Biosuccess Biotech Co Ltd Compositions and methods of use of phorbol esters for the treatment of stroke
WO2013112363A1 (en) * 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
CN108517014A (zh) * 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
ES2822004T3 (es) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticuerpos contra quetiapina y uso de los mismos
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
AU2013305901B2 (en) 2012-08-21 2017-10-26 Saladax Biomedical Inc. Antibodies to olanzapine and use thereof
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールハプテンに対する抗体及びその使用
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
JP2015529199A (ja) * 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
JP6450314B2 (ja) 2012-08-21 2019-01-09 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンハプテンに対する抗体及びその使用
JP6389177B2 (ja) * 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA2904539C (en) 2013-03-15 2022-05-03 Melior Discovery, Inc. Methods of treating dyskinesia and related disorders
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2015098591A1 (ja) * 2013-12-25 2015-07-02 株式会社フジモト・コーポレーション 注意欠如・多動性障害の予防および治療剤
US20170173039A1 (en) * 2014-04-02 2017-06-22 Yale University Compositions and methods to treat addiction
WO2015200049A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
JP6655090B2 (ja) * 2015-01-28 2020-02-26 ジェネリス コリア コーポレーション 神経精神系障害の治療のための組成物および方法
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN106361734A (zh) * 2015-07-25 2017-02-01 云南帕精生物科技有限公司 一类治疗精神分裂症药物
US10662146B2 (en) * 2015-09-15 2020-05-26 Praxis Bioresearch, LLC Prodrugs of fencamfamine
CN106562945A (zh) * 2015-10-11 2017-04-19 云南帕精生物科技有限公司 一类治疗帕金森病药物
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
CN105456214A (zh) * 2015-12-30 2016-04-06 蔡惠文 甲磺酸沙芬酰胺片
WO2018206924A1 (en) * 2017-05-09 2018-11-15 Zogenix International Limited Methods of treating doose syndrome using fenfluramine
FI3661491T3 (fi) * 2017-08-03 2025-06-26 Ezekiel Golan 3-metyylimetkatinoni käytettäväksi psykoterapeuttisessa interventiossa olevan henkilön hoidossa
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP4230197A3 (en) * 2017-10-23 2024-01-24 Cerebral Therapeutics LLC High concentration medicant solutions for treating neurological disorders
MY210372A (en) * 2017-11-14 2025-09-16 Univ Osaka Cognitive impairment diagnostic apparatus and cognitive impairment diagnostic program
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
JP7730548B2 (ja) * 2019-04-18 2025-08-28 プリヴェップ インコーポレイテッド 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法
CA3139288A1 (en) * 2019-05-23 2020-11-26 Ramachandra MUKUNDA Compositions and methods using cannabinoids for treating stammering/stutering and symptoms of tourette syndrome
WO2021038460A1 (en) 2019-08-26 2021-03-04 Period Pill Bv Treatment of menstrual cycle-induced symptoms
US12014835B2 (en) * 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
RU2743876C1 (ru) * 2020-05-19 2021-03-01 Татьяна Евгеньевна Ефремова Способ реабилитации детей и подростков с поведенческими и эмоциональными нарушениями, страдающих психическими расстройствами
CA3204682A1 (en) 2020-12-09 2022-06-16 Eysz, Inc. Systems and methods for monitoring and managing neurological diseases and conditions
US20240197704A1 (en) * 2021-04-09 2024-06-20 Johns Hopkins University Treatment methods and compositions comprising perampanel
EP4334282A4 (en) * 2021-05-05 2025-03-19 Mind Medicine, Inc. ENANTIOMERS OF MDMA
WO2022265534A1 (ru) * 2021-06-18 2022-12-22 Гиви Иванович ИКАЕВ Способ коррекции психического состояния больного шизофренией
CN117956994A (zh) * 2021-07-08 2024-04-30 Nls制药股份公司 用于治疗克莱恩-莱文综合症的贝尼丁，哌啶，2-二苯甲基-3-羟基-n-甲基-，盐酸盐及其衍生物
EP4444283A4 (en) * 2021-12-09 2025-11-12 Tactogen Inc SPECIALIZED COMBINATIONS FOR TREATING MENTAL DISORDERS OR IMPROVING MENTAL STATE
US20250375129A1 (en) * 2022-02-11 2025-12-11 Blinktbi, Inc. Use of blink reflex for attention-deficit/hyperactivity disorder (adhd) response monitoring and/or treatment selection
WO2024123706A1 (en) * 2022-12-05 2024-06-13 Lykos Therapeutics, Inc. Compositions comprising mdma and methods of using same
CN116831580B (zh) * 2023-08-31 2023-12-01 北京中科心研科技有限公司 识别抑郁情绪障碍的计算设备应用、装置及可穿戴设备
US12475781B2 (en) 2023-12-08 2025-11-18 Toyota Motor Engineering & Manufacturing North America, Inc. Systems and methods for detecting impaired decision-making pedestrians
WO2025196662A1 (en) 2024-03-20 2025-09-25 Clearmind Labs Corp. Compositions and methods for treating eating disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515564A (ja) * 1999-12-01 2003-05-07 ユセベ，ソシエテ アノニム Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
WO2007115997A2 (de) * 2006-04-04 2007-10-18 Holger Lars Hermann Kombinationspräparate aus modafinil, ritalin und topiramat bei kokainabhängigkeit und/oder zur behandlung von impulskontrollstörungen

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5603956A (en) 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
GB9209599D0 (en) 1992-05-02 1992-06-17 Fisons Corp Novel therapy for the treatment of parkinsons disease
GB9215043D0 (en) 1992-07-15 1992-08-26 Flow Inc K Fluid mass flow meters
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5397574A (en) 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5399358A (en) 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
DE69535127T2 (de) 1994-03-18 2007-02-15 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US6103263A (en) 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
DE69735002T2 (de) 1996-10-25 2006-10-26 Shire Laboratories, Inc. Osmotisches Verabreichungssystem für lösliche Dosen
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
DE69818607T2 (de) 1997-05-30 2004-07-29 Osmotica Corp. Mehrlagige osmosevorrichtung
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US20020102291A1 (en) 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6106862A (en) 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6417184B1 (en) * 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
US8354438B2 (en) * 2001-08-08 2013-01-15 Michael Chez Neurological functions
WO2003013514A1 (en) 2001-08-08 2003-02-20 Carn-Aware Llc Improving neurological functions
WO2003020289A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
ATE353645T1 (de) 2001-10-08 2007-03-15 Ucb Sa Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
FR2837100B1 (fr) 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
CA2488566A1 (en) 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
US7390505B2 (en) * 2003-01-31 2008-06-24 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
FR2861990B1 (fr) 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
DE202005020881U1 (de) 2004-08-23 2006-12-07 PEJO Iserlohn Heilmittel und Diät GmbH & Co. KG Psychostimulans enthaltende pharmazeutische Zusammensetzung
BRPI0520258A2 (pt) * 2005-05-06 2009-09-15 Portela & Ca Sa uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
US20080057123A1 (en) 2006-08-30 2008-03-06 Jagotec Ag Controlled Release Formulations
AU2007346591A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
AU2008279636A1 (en) * 2007-07-25 2009-01-29 The Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for CNS conditions
US20110065628A1 (en) * 2007-08-27 2011-03-17 University Of Virginia Patent Foundation Medication Combinations for the Treatment of Alcoholism and Drug Addiction
WO2009139901A2 (en) 2008-05-14 2009-11-19 The Johns Hopkins University Methods and compositions for improving cognitive function
JP2011529923A (ja) 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
WO2011143721A1 (en) 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515564A (ja) * 1999-12-01 2003-05-07 ユセベ，ソシエテ アノニム Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
WO2007115997A2 (de) * 2006-04-04 2007-10-18 Holger Lars Hermann Kombinationspräparate aus modafinil, ritalin und topiramat bei kokainabhängigkeit und/oder zur behandlung von impulskontrollstörungen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013027170; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｉｌｄ　ａｎｄ　Ａｄｏｌｅｓｃｅｎｔ　Ｐｓｙｃｈｏｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．８，　Ｎｏ．１, 1998, ｐ．４９-５９ *
JPN6013027171; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｉｌｄ　ａｎｄ　Ａｄｏｌｅｓｃｅｎｔ　Ｐｓｙｃｈｏｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．１１，　Ｎｏ．３, 2001, ｐ．３０１-３０９ *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230033195A1 (en) * 2011-02-09 2023-02-02 The Johns Hopkins University Methods and compositions for improving cognitive function
US9421188B2 (en) 2012-03-23 2016-08-23 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Combination product comprising phentermine and topiramate, and preparation method thereof
JP2015510901A (ja) * 2012-03-23 2015-04-13 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ シネフリン及びトピラマートを含む組み合わせ製品
US12097206B2 (en) 2013-05-03 2024-09-24 Katholieke Universiteit Leuven Method for the treatment of Dravet Syndrome
JP2016537435A (ja) * 2013-11-20 2016-12-01 ビオコデ 強迫神経症の薬理学的治療
JP2016540815A (ja) * 2013-12-18 2016-12-28 ビオコデ 注意欠陥及び／又は多動の治療における使用のためのベンゾジオキソール誘導体
JP2017528478A (ja) * 2014-09-10 2017-09-28 ロイヤル・ホロウェイ・アンド・ベッドフォード・ニュー・カレッジＲｏｙａｌ Ｈｏｌｌｏｗａｙ Ａｎｄ Ｂｅｄｆｏｒｄ Ｎｅｗ Ｃｏｌｌｅｇｅ 抗痙攣化合物
JP2021007038A (ja) * 2014-09-29 2021-01-21 ゾゲニクス インターナショナル リミテッド 薬物供給管理用の管理システム
JP2018521127A (ja) * 2015-07-08 2018-08-02 ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
JP2021088571A (ja) * 2015-07-08 2021-06-10 ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
JP7350794B2 (ja) 2015-07-08 2023-09-26 ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
JP7016169B2 (ja) 2015-12-11 2022-02-04 オーフス ウニベルシテット 筋強直症の治療における使用のためのルフィナミド
US12023322B2 (en) 2015-12-11 2024-07-02 Aarhus Universitet Rufinamide for use in the treatment of myotonia
JP2018536688A (ja) * 2015-12-11 2018-12-13 オルフス ユニバーシテト 筋強直症の治療における使用のためのルフィナミド
US11634377B2 (en) 2015-12-22 2023-04-25 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
US11673852B2 (en) 2015-12-22 2023-06-13 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
JP7073272B2 (ja) 2016-05-12 2022-05-23 リサーチ トライアングル インスティテュート 神経伝達物質放出剤としてのビニローグフェネチルアミン
JP2022101537A (ja) * 2016-05-12 2022-07-06 リサーチ トライアングル インスティテュート 神経伝達物質放出剤としてのビニローグフェネチルアミン
JP2019520311A (ja) * 2016-05-12 2019-07-18 リサーチ トライアングル インスティテュート 神経伝達物質放出剤としてのビニローグフェネチルアミン
JP7343641B2 (ja) 2016-05-12 2023-09-12 リサーチ トライアングル インスティテュート 神経伝達物質放出剤としてのビニローグフェネチルアミン
US11759440B2 (en) 2016-08-24 2023-09-19 Zogenix International Limited Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
US11786487B2 (en) 2016-08-24 2023-10-17 Zogenix International Limited Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
US11406606B2 (en) 2016-08-24 2022-08-09 Zogenix International Limited Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
US11458111B2 (en) 2017-09-26 2022-10-04 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
JP2024505283A (ja) * 2021-02-03 2024-02-05 マリオ サンチェス，エクトル 遂行機能障害の処置のための併用療法

Also Published As

Publication number Publication date
US20160000815A1 (en) 2016-01-07
EP2331088A1 (en) 2011-06-15
WO2010015029A1 (en) 2010-02-11
CN102170874A (zh) 2011-08-31
US20110207718A1 (en) 2011-08-25
AU2009279372A1 (en) 2010-02-11
US10028971B2 (en) 2018-07-24
CA2732131A1 (en) 2010-02-11
MX2011001384A (es) 2011-09-27
EP2331088A4 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
JP2011529923A (ja) 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
JP5586962B2 (ja) Ａｄｈｄの治療
US20140142140A1 (en) Pharmaceutical composition for neurological disorders
CA2580619C (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
Iancu et al. Pathological gambling: an update on neuropathophysiology and pharmacotherapy
AU2002311784B2 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
CA3188263A1 (en) Intravenous dmt administration method for dmt-assisted psychotherapy
US11752111B2 (en) Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia
JP6196239B2 (ja) 精神及び行動の障害治療剤
Berlin et al. Understanding the differences between impulsivity and compulsivity
Joralemon How Ketamine Became an Antidepressant
US20220062265A1 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
Furniss et al. Neurobiology of self-injurious behavior
JP2019514978A (ja) イブジラストを使用したアルコール依存症並びにうつ病及び／又は不快な気分の治療
WO2020018779A1 (en) Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction
Mutlu et al. Pharmacological treatments for gambling disorder: a current review of literature
Medina-Kirchner A Multi-Level Analysis of Amphetamine Derivatives: Repeated 3, 4-Methylenedioxymethamphetamine Administration and Popular Methamphetamine Combinations in Mice and Humans
Mahmood et al. Narcolepsy-cataplexy: how does recent understanding help in evaluation and treatment
Soffer et al. A psychodynamic understanding of conversion nonepileptic seizures in a young woman with acquired blindness
Stevenson Factors underlying natural reward devaluation by cocaine: Effects of dose and exercise
JP6585598B2 (ja) 注意欠陥及び／又は多動の治療における使用のためのベンゾジオキソール誘導体
Qureshi et al. Misdiagnosis and a suicide attempt: the importance of accurate evaluation and treatment
Latoo et al. Often overlooked neuropsychiatric syndromes in Parkinson's disease.
Mackenzie Gary Alan-Hue Christenson
DONAHUE et al. Stress and Impulsive

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120803

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140930

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20141215